Clinical Trials

25 enrolled

Carcinoma, Hepatocellular

NCT04686305 2026-04-13

DL03

304 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04612751 2026-04-06

TROPION-Lung04

155 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07107750 2026-04-03

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

48 enrolled

Biliary Tract Neoplasms

NCT03923270 2026-04-01

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

25 enrolled

Lung Neoplasms, Small Cell Lung Carcinoma

NCT02537418 2026-03-27

Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens

153 enrolled

Solid Malignancies

NCT02997332 2026-03-23

MEDINDUCTION

Phase 1 Terminated

14 enrolled

Head & Neck

Head and Neck Neoplasms

NCT04387084 2026-03-23

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

10 enrolled

Dermatologic

Skin Neoplasms

NCT03258593 2026-03-17

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

15 enrolled 21 charts

Genitourinary

Urinary Bladder Neoplasms, Carcinoma in Situ

NCT06083454 2026-03-13

Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC)

Phase 1 Terminated

1 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05733689 2026-03-10

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

20 enrolled

Gastroesophageal Adenocarcinoma

NCT05514132 2026-03-09

A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours

14 enrolled

Other solid neoplasm

Advanced Solid Tumours

NCT06963346 2026-03-09

Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents

Phase 1 Suspended

12 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT04900818 2026-03-05

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

330 enrolled

Adenocarcinoma Of Esophagus, Biliary Tract Neoplasms, Neoplasm Metastasis, Stomach Neoplasms

NCT02617277 2026-03-04

Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours

56 enrolled

Other solid neoplasm

Advanced Solid Tumours

NCT05361395 2026-03-03

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

184 enrolled

Bites and Stings, Lung Neoplasms

NCT05403723 2026-02-19

Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC

Phase 1 Suspended

50 enrolled

Lung Neoplasms, Small Cell Lung Carcinoma

NCT05443971 2026-02-06

Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC Regimen

Phase 1 Terminated

4 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05155189 2026-01-21

A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma

72 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06302426 2026-01-16

Trial of INI-4001 in Patients With Advanced Solid Tumours

50 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT06124118 2026-01-08

NOVOCURE

30 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02546661 2025-12-29

BISCAY

117 enrolled

Genitourinary

Muscle Invasive Bladder Cancer

NCT06218511 2025-12-22

A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1)

10 enrolled

Carcinoma, Hepatocellular

NCT04550104 2025-12-19

CONCORDE

200 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04556773 2025-12-17

DB-08

138 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06546969 2025-12-10

Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer

15 enrolled

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT03257761 2025-12-05

Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer

55 enrolled

Gallbladder Neoplasms, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Cholangiocarcinoma

NCT03381183 2025-12-05

IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma

19 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT03983954 2025-11-28

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

120 enrolled

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT02639026 2025-11-25

Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers

BreastDermatologicGastrointestinalThoracic

53 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms

NCT04895579 2025-11-18

LCD

11 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02826434 2025-10-01

Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer

22 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03801902 2025-09-23

Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial

26 enrolled 17 charts

Lung Neoplasms

NCT03019003 2025-09-16

Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients

13 enrolled 12 charts

Head & Neck

Head and Neck Neoplasms

NCT03085225 2025-09-04

TRAMUNE

40 enrolled 23 charts

GynecologicSarcoma

Ovarian Neoplasms, Sarcoma

NCT05701488 2025-09-02

SIRT With Tremelimumab and Durvalumab for Resectable HCC

20 enrolled